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Key Points
• TP53 mutations corre-
late with enhanced im-
mune infiltration and
high levels of actionable
immune checkpoints in
AML.
• TP53 mutations asso-
ciate with complete
responses to flotetuzu-
mab, an investigational
immunotherapy, in R/R
AML.
Somatic TP53mutations and 17p deletions with genomic loss of TP53 occur in 37% to 46% of
acute myeloid leukemia (AML) with adverse-risk cytogenetics and correlate with primary
induction failure, high risk of relapse, and dismal prognosis. Herein, we aimed to characterize
the immune landscape of TP53-mutated AML and determine whether TP53 abnormalities
identify a patient subgroup that may benefit from immunotherapy with flotetuzumab, an
investigational CD123 3 CD3 bispecific dual-affinity retargeting antibody (DART) molecule.
The NanoString PanCancer IO360 assay was used to profile 64 diagnostic bone marrow (BM)
samples frompatientswith TP53-mutated (n5 42) and TP53-wild-type (TP53-WT) AML (n5 22)
and 45 BM samples from patients who received flotetuzumab for relapsed/refractory (R/R)
AML (15 cases with TP53 mutations and/or 17p deletion). The comparison between TP53-
mutated and TP53-WT primary BM samples showed higher expression of IFNG, FOXP3,
immune checkpoints, markers of immune senescence, and phosphatidylinositol 3-kinase-Akt
and NF-kB signaling intermediates in the former cohort and allowed the discovery of a 34-
gene immune classifier prognostic for survival in independent validation series. Finally, 7 out
of 15 patients (47%) with R/R AML and TP53 abnormalities showed complete responses to
flotetuzumab (,5% BM blasts) on the CP-MGD006-01 clinical trial (NCT #02152956) and had
significantly higher tumor inflammation signature, FOXP3, CD8, inflammatory chemokine,
and PD1 gene expression scores at baseline compared with nonresponders. Patients with
TP53 abnormalities who achieved a complete response experienced prolonged survival
(median, 10.3 months; range, 3.3-21.3 months). These results encourage further study of
flotetuzumab immunotherapy in patients with TP53-mutated AML.
Submitted 4 June 2020; accepted 24 August 2020; published online 15 October
2020. DOI 10.1182/bloodadvances.2020002512.
*J.V. and C.L. contributed equally to this study.
The data reported in this article have been deposited in the Gene Expression Omnibus
database (accession number GSE146204). The results shown in this paper are in part
based upon data generated by the TCGA Research Network (https://www.cancer.
gov/tcga).
The full-text version of this article contains a data supplement.
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Introduction
Acute myeloid leukemia (AML) is a molecularly and clinically
heterogeneous disease. The patients with the poorest outcomes
are those with refractory disease, including individuals with primary
induction failure (PIF) who fail initial induction attempts.1 Complex
karyotypes, including deletions affecting chromosome arm 17p,
frequently coexist with TP53 mutations and define a “very unfavor-
able” subgroup of AML with a 5-year relapse-free survival (RFS) and
overall survival (OS) of 0%.2-4 Somatic TP53 mutations and
deletions of 17p, to which TP53 is mapped, occur in 8% to 10%
of de novo AML5-7 and in up to 37% to 46% of patients with adverse-
risk cytogenetics and treatment-related myeloid neoplasms.2,8 Further-
more, patients with mutated TP53 and/or 17p deletion tend to be older
and have low performance status, and therefore, only a few of them are
candidates for allogeneic hematopoietic stem cell transplantation
(HSCT), which offers the highest curative potential.9 Response rates
to standard-of-care (SOC) cytarabine-based induction chemotherapy
in patients with TP53-mutated AML range between 14% and 42%,
with a median OS of 2 to 12 months.2,5 In the relapsed and refractory
(R/R) setting, where TP53 mutations are highly prevalent, response
rates to standard salvage cytotoxic regimens are ,20%.2,10,11
Emerging evidence implicates mutant TP53, in addition to its well-
characterized function as a tumor suppressor, in activating genes
involved in immune responses and inflammation, including chemo-
kines, cytokines, and extracellular matrix modulators.12 A recent
analysis of The Cancer Genome Atlas (TCGA) transcriptomic data
from 10000 nonhematologic tumors has indicated that TP53
mutations correlate with increased leukocyte infiltration across 30
diverse cancer types and are enriched in the C1 (wound healing)
and C2 (interferon-g [IFN-g] dominant) immune subtypes.13
Importantly, higher proportions of PD-L1–expressing CD81
T cells, higher tumor mutational burden, and increased expression
of T-cell effector genes and IFN-g–related genes associate with
favorable responses to pembrolizumab immunotherapy in patients
with TP53-mutated lung cancer.14
We have recently identified microenvironmental immune gene sets
that capture elements of both type I– and IFN-g–driven biology and
stratify newly diagnosed AML into an immune-infiltrated and an
immune-depleted subtype.15 Our immune classifier increased the
accuracy of survival prediction in patients receiving cytarabine-
based induction chemotherapy beyond the current capabilities of
individual molecular markers. Herein, we aimed to investigate
whether TP53 mutations shape the immune landscape of AML and
whether they identify patients that derive benefit from flotetuzumab,
an investigational CD1233 CD3 bispecific dual-affinity retargeting
antibody (DART) molecule.16
Materials and methods
Patient demographics and study approval
Patient and disease characteristics as well as induction treatment
regimens are summarized in Table 1. TP53 mutational status is
detailed in supplemental Tables 1 and 2. The first wet-laboratory
cohort consisted of 40 primary bone marrow (BM) samples
from patients with newly diagnosed, TP53-mutated AML treated
with curative intent (SAL cohort). The second wet-laboratory
cohort included 24 primary BM samples from patients with
newly diagnosed AML treated with curative intent (Bologna
cohort; 2 cases with mutated TP53). The third wet-laboratory
cohort consisted of 45 primary BM samples from patients with
PIF, early-relapse AML (duration of complete remission 1 [CR1]
,6 months), and late-relapse AML (duration of CR1 $6
months) treated with flotetuzumab at the recommended phase
2 dose (500 ng/kg per day) on the CP-MGD006-01 clinical trial
(NCT #02152956). Patients with prior HSCT were ineligible.
Fifteen patients from the flotetuzumab cohort harbored TP53
mutations or 17p deletions with genomic loss of TP53. Patients
received a lead-in dose of flotetuzumab during week 1, followed by
500 ng/kg per day during weeks 2 to 4 of cycle 1 and a 4-day on/
3-day off schedule for cycle 2 and beyond. Disease status was
assessed by modified International Working Group criteria.17
Specifically, complete responses were defined as either CR, CR
with partial hematological recovery (CRh), CR with incomplete
Table 1. Patient series
Wet laboratory
In silico
SAL Bologna TCGA*
No. of patients 40 24 147
Males/females, n 26/14 17/7 81/66
Age, n
0-14 y 0 0 0
15-39 y 2 3 27
40-59 y 13 12 45
.60 y 25 9 75
WBC count at presentation, median
(range), 3103/mL
10.55 (0.8-
218.5)
45 (1.5-
153)
20 (1-297)
Percentage of BM blasts, median (range) 63.7 (30-90) 16.5 (0.4-
57)
72 (11-99)
Cytogenetic risk group, n (%)
ELN favorable 0 (0) 6 (26.1) 17 (12)
ELN intermediate 0 (0) 7 (30.4) 96 (65)
ELN adverse 40 (100) 5 (21.7) 32 (22)
NA 0 (0) 5 (21.7) 2 (1)
TP53 status
Mutated 40 2 14
WT 0 22 —
Not tested/not available — — 133
Induction chemotherapy
7 1 3 5 2 113
Fludarabine based — 8 —
Daunorubicin 1 cytarabine 21 0 —
MAV 12 5 —
HMAs — 3 14
Lenalidomide 1 — 9
Other 1 6 11
Cohort-wide OS (mo from diagnosis),
median (range)
5.06 (0.03-
158.3)
16.5 (0.3-
57)
15.5 (0.1-
118.1)
SAL, Studien-Allianz Leuka¨mie; ELN, European Leukemia-Net; HMAs, hypomethylating
agents; MAV, mitoxantrone, cytarabine, and etoposide; WBC, white blood cell.
*Cases of newly diagnosed nonpromyelocytic AML with RNA-sequencing data and
clinical annotation.
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Figure 1. TP53 mutations correlate with an immune-infiltrated TME in TCGA-AML. (A) Heatmap of immune-cell-type–specific scores and biological activity scores in
TCGA-AML cases with information on prognostic molecular lesions (n 5 118; unsupervised hierarchical clustering; Euclidean distance; complete linkage). ClustVis, an online
tool for clustering of multivariate data, was used for data analysis and visualization.47 The optimal number of clusters was defined through silhouette scoring using an open-
source machine learning toolkit (Orange3, version 3.25.0). FLT3-ITD, fms-like tyrosine kinase 3 internal tandem duplication; NPM1, nucleophosmin-1. ELN intermediate cases
were further subclassified into molecular low-risk cases (NPM1 mutations without FLT3-ITD) and molecular high-risk cases (NPM1 WT with FLT3-ITD).22 (B) Fraction of
genome altered in TCGA-AML cases with TP53 mutations (n 5 14) and other prognostic molecular lesions (n 5 104). Bars denote median values. Data were retrieved
through cBioPortal and were compared using the Mann-Whitney U test for unpaired determinations. (C) Box plots showing immune signature scores in TCGA-AML cases with
TP53 mutations (n 5 14) and other prognostic molecular lesions (n 5 19 with NPM1 mutations; n 5 22 with RUNX1 mutations; n 5 48 with FLT3-ITD without NPM1
mutations; n 5 15 with CHIP-defining mutations). Data were compared using the Kruskal-Wallis test for unpaired determinations with Bonferroni’s correction for multiple
comparisons. (D) TIS, inflammatory chemokine, IFN-g, and lymphoid signature scores in TCGA cases with TP53 mutations with (n 5 9 cases) or without a CK (n 5 13 cases)
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hematological recovery (CRi), or morphological leukemia-free
state (MLFS) at the end of cycle 1. Other responses were defined
as either partial response (.50% decrease in BM blasts from
baseline or decrease to 5% to 25% BM blasts) or other benefit
(.30% reduction of BM blasts from baseline) at the end of cycle
1. Human studies were approved by the institutional review boards
at SAL (Germany) and the University of Bologna (Italy), and by the
institutional review boards of the centers participating to the
flotetuzumab immunotherapy clinical trial. Written informed consent
was received from all participants prior to inclusion in the study.
Details on immune gene expression profiling, in silico data sources,
gene set enrichment analysis, in vitro propagation of AML cell lines
and flow cytometry-based assays are provided in the supplemental
Appendix and in previous publications.15,18
Statistical analyses
Descriptive statistics included calculation of mean, median,
standard deviation, and proportions to summarize study out-
comes. Comparisons were performed with the Mann-Whitney
U test for paired or unpaired data (2 sided), as appropriate, or
with the analysis of variance with correction for multiple comparisons.
A 2-tailed P , .05 was considered to reflect statistically significant
differences. The log-rank (Mantel-Cox) test was used to compare
survival distributions. OSwas computed from the date of diagnosis to
the date of death. RFS was measured from the date of first CR to the
date of relapse or death. Subjects lost to follow-up were censored at
their date of last known contact. IBM SPSS Statistics (version 24)
and GraphPad Prism (version 8) were used for statistical analyses.
Results
TP53 mutational status correlates with immune
infiltration in TCGA-AML cases
We first asked whether the expression of known AML drivers,
including TP53, correlates with the immune composition and
functional orientation of the BM tumor microenvironment (TME). To
address this hypothesis, we retrieved RNA-sequencing data with
cytogenetic and clinical annotation, including RFS and OS, from
adult patients with newly diagnosed, nonpromyelocytic AML
profiled in the TCGA project (n 5 147 cases available through
cBioPortal for Cancer Genomics; n 5 118 cases with information
on prognostic molecular lesions). Signature scores that identify
immune subtypes of AML with poor sensitivity to induction
chemotherapy and worse clinical outcomes were derived from
messenger RNA (mRNA) expression, as previously published
(supplemental Table 1),15,19 and included the tumor inflamma-
tion signature (TIS), an established predictor of response to
immune checkpoint blockade in solid tumors.20,21 ELN in-
termediate cases with information on NPM1 mutational status
and FLT3-ITD were further subclassified into molecular low
risk (NPM1 mutations without FLT3-ITD) and molecular high
risk (NPM1 wild-type [WT] with FLT3-ITD).22 TP53 mutations (8
missense, 3 frameshift, 3 splice site, 1 nonsense, and 1 homozygous
deletion) were present in 14 patients (lollipop plot in supplemental
Figure 1A and supplemental Table 2). TP53-mutated cases harboring
comutations in genes with known prognostic relevance in AML, such
as DNMT3A and TET2,23-25 were excluded from the analysis
(supplemental Figure 1B). As expected, median OS from diagnosis
was 4.5 months in TCGA cases with mutated TP53 compared with
18.5 months in patients with other prognostic molecular lesions
(hazard ratio [HR, 3.43; P , .0001; supplemental Figure 1C).
As shown in Figure 1A-B, TP53-mutated AML cases showed higher
immune infiltration, a higher number of mutations, and a higher
fraction of genome altered (fraction of copy-number–altered chromo-
some regions out of measured regions), consistent with the role of
mutant TP53 in promoting genomic instability,26 compared with
patients harboring other high-risk molecular features (NPM1 WT with
FLT3-ITD) and patients with low or intermediate risk. The TIS score
was significantly higher in TP53-mutated cases relative to cases with
molecular lesions associated with favorable clinical outcomes (NPM1
mutations without FLT3-ITD) and cases with clonal hematopoiesis of
indeterminate potential (CHIP)–defining mutations in ASXL1, TET2,
and DNMT3A (P , .0001; Figure 1C). Overall, the higher IFN-g
signaling, inflammatory chemokine, and lymphoid scores in patients
with TP53 mutations suggested a higher degree of immune infiltration
and the activation of IFN-g–related signaling pathways (Figure 1C).
TP53 alterations commonly occur in patients with complex karyotype
(CK) AML.4 As shown in Figure 1D, the TIS, IFN-g signaling,
inflammatory chemokine, and lymphoid signature scores were higher
in TP53-mutated AML than CK AML with WT TP53. This observation
suggests that changes in immune gene expression are unlikely to be
attributable to chromosome gains and losses.
The expression of actionable immune checkpoints (PD-L1 and
TIGIT) and genes associated with a highly immune-suppressed
TME, such as the regulatory T (Treg) cell transcription factor
FOXP3, was higher in TP53-mutated cases (Figure 1E; P
values adjusted for multiple testing). Gene set enrichment
analysis using published gene sets from landmark studies
characterizing CD81 T-cell dysfunction in AML (supplemental
Table 3),27 as well as curated gene sets from the Molecular
Signature Database, indicated functional enrichment of an
immune senescence–related 8-gene set in TCGA-AML cases
with TP53 mutations (supplemental Figure 2A-B). In contrast,
no enrichment was observed in TP53-mutated cases when
probing gene sets defining T-cell exhaustion (supplemental
Figure 2A). The enrichment of TP53-mutated BM samples with
CD81 T cells, Treg cells, and other innate and adaptive immune
cell types was validated using CIBERSORT, a deconvolution
algorithm that allows the enumeration of 22 functionally defined
hematopoietic cell subsets from gene expression profiles, including
T-cell subsets, naive and memory B cells, plasma cells, natural killer
cells, and myeloid-cell subsets (supplemental Figure 2C).28 The
increased T-cell frequency in TP53-mutated AML (n5 3) compared
with TP53-WT AML (n 5 13) and BM samples from healthy donors
(n 5 4) was also confirmed using publicly available single-cell RNA-
sequencing datasets (GSE116256; supplemental Figure 3).29
Figure 1. (continued) for whom immune gene signature scores could be computed. Data were compared using the Mann-Whitney U test for unpaired determinations. (E)
Expression of FOXP3 and immune checkpoints PD-L1 and TIGIT in TCGA-AML cases with TP53 mutations (n 5 14) and other prognostic molecular lesions (n 5 104). Bars
denote median values. Data were compared using the Mann-Whitney U test for unpaired determinations. ND, not determined.
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Figure 2. TP53-related cancer pathways and expression of actionable immune checkpoints in patients with TP53-mutated AML (SAL and Bologna cohorts).
(A) TP53 mutations were categorized as missense or no missense (frameshift, splice site and nonsense) using the IARC TP53 database (http://p53.iarc.fr/) and based on prior
knowledge.30,31 (B) Principal-component (PC) analysis of 770 immune genes (IO 360 panel) in patients with TP53-mutated (n 5 42) and TP53WT AML (n 5 22). Points are
colored by TP53 mutational status (mutated, red; WT, blue). ClustVis was used for data analysis and visualization. (C) Heatmap of immune-cell-type–specific and biological
activity scores in patients with TP53-mutated and TP53-WT AML (unsupervised hierarchical clustering; Euclidean distance; complete linkage). The number of TP53-mutated
cases in each immune cluster (high, intermediate, and low) is indicated. ClustVis, an online tool for clustering of multivariate data, was used for data analysis and visualization.
(D) Heatmap of cancer pathway scores in patients with TP53-mutated and TP53-WT AML (unsupervised hierarchical clustering; Euclidean distance; complete linkage).
(E) Cancer pathway scores in patients with TP53-mutated and TP53-WT AML. Bars denote median values. Data were compared using the Kruskal-Wallis test for unpaired
determinations. (F) Box plots summarizing the expression of negative immune checkpoints and immune genes related to T-cell infiltration, regulatory T cells, and cytolytic activity
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Primary BM samples from patients with
TP53-mutated AML express inflammatory and
IFN-related gene sets
We next compared immune gene expression profiles between bulk
BM specimens from patients with TP53-mutated (n5 42) and TP53-
WT AML (n 5 22). The predicted functional consequences
of TP53 mutations (84% missense; Figure 2A) are listed in
supplemental Table 4 and were inferred using the IARC TP53
database (http://p53.iarc.fr/) and prior knowledge.30,31 These
data are in agreement with the reported frequency of TP53
missense mutations (83.7%) in the German-Austrian AML
series.32 Our set of predefined immune-cell-type–specific
scores and biological activity scores distinguished patients
with TP53-mutated AML from individuals with TP53-WT AML,
as highlighted by data dimensionality reduction using principal-
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Figure 3. Identification of a TP53-related immune gene set in patients with TP53-mutated AML (SAL and Bologna cohorts). (A) Volcano plot (R package version
1.4.0) showing DE genes (P threshold 5 .01; log2 fold change $1.5) between patients with TP53-mutated (n 5 42) and TP53-WT AML (n 5 22). B) Heatmap displaying the
34 genes with the greatest differential expression between patients with TP53-mutated and TP53-WT AML (P threshold 5 .01; log2 fold change $1.5). ClustVis, an online tool for
clustering of multivariate data, was used for data analysis and visualization. (C) Analysis of functional protein association networks using STRING (https://string-db.org/). Top 10
molecules interacting with DE genes between TP53-mutated and TP53-WT AML are shown together with their predicted mode of action (highest-confidence interaction scores
.0.900). Network nodes (query proteins) represent proteins produced by a single protein-coding gene locus. White nodes represent second shells of interactors. Empty and filled
nodes indicate proteins of unknown or partially known 3-dimensional structure, respectively. Edges represent protein-protein associations. Line shapes denote predicted modes of
action. (D) Correlation between abnormalities of genes in the TP53 immune classifier and prognostic molecular lesions, including TP53 mutations, in TCGA-AML cases. Data were
retrieved and analyzed using cBioPortal for Cancer Genomics (http://www.cbioportal.org/) and were compared using the Fisher’s exact test. NS, not significant.
Figure 2. (continued) in patients with TP53-mutated and TP53-WT AML. Bars denote median values. Data were compared using the Mann-Whitney U test for unpaired
determinations. NA, not available; PI3K, phosphatidylinositol 3-kinase.
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component analysis (Figure 2B). The frequency of TP53-
mutated cases in patients with high, intermediate, and low
immune infiltration was 87% (n 5 20/23), 75% (n 5 21/28),
and 8% (n 5 1/13), respectively (Figure 2C). We also
computed scores that capture frequently dysregulated signal-
ing pathways in cancer using predefined sets of relevant genes.
As shown in Figure 2D, TP53-mutated cases expressed higher
amounts of NF-kB, JAK/STAT, and phosphatidylinositol 3-kinase
(PI3K)-Akt signaling molecules relative to BM samples from
patients with TP53-WT AML. In contrast, DNA damage repair
genes as well as Hedgehog and Wnt signaling pathway genes
were upregulated in TP53-WT compared with TP53-mutated
AML (Figure 2E). These findings are congruent with previous
studies showing that TP53 is a suppressor of canonical Wnt
signaling in solid tumors.33 TP53-mutated AML also expressed
IFNG, FOXP3, PD-L1, LAG3, CD8A, PTGER4, and GZMB
(Figure 2F), a molecule recently associated with features of
exhaustion and senescence in AML-infiltrating CD81 T cells27
and with worse clinical outcomes.15
We next analyzed the immune transcriptomic profile at the gene
level, and we identified a set of 34 differentially expressed (DE)
immune genes at a false discovery rate ,0.01 between patients
with TP53-mutated and TP53-WT AML (Figure 3A-B; supple-
mental Table 5). The TP53 immune signature genes have not
been previously implicated in the TP53 pathway (supplemental
Figure 4A). Neutrophil chemoattractants (proinflammatory CXCL1,
CXCL2, and CXCL8 or IL8) and IFN-inducible molecules
such as CCL2, IL33, IL6, OASL, and RIPK2 were more
highly expressed in TP53-mutated compared with TP53-
WT patients. The DE genes exhibited enrichment of Gene
Ontology and Kyoto Encyclopedia of Genes and Genomes
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Figure 4. Upregulated genes in the TP53 immune gene classifier correlate with immune infiltration in TCGA-AML cases. (A) Heatmap of immune-cell-type–
specific scores and biological activity scores (unsupervised hierarchical clustering; Euclidean distance; complete linkage) in TCGA-AML cases with (n 5 93) or without
(n 5 54) abnormalities in the DE genes (TP53 immune classifier) between patients with TP53-mutated (n 5 42) and TP53-WT AML (n 5 22). Abnormalities were defined
as mRNA upregulation, gene amplification, deep deletion, and missense mutations relative to the gene’s expression distribution in all profiled AML samples. Abnormalities
in only 1 gene used in the cBioPortal query (by default, nonsynonymous mutations, fusions, amplifications, and deep deletions) were sufficient to define that particular
patient sample as “altered." (B) Expression of IFN-g signaling molecules, immune checkpoints, and markers of T-cell infiltration in TCGA-AML cases with or without
abnormalities in the TP53 classifier genes. Bars denote median values. (C) Abnormalities in the 18 upregulated immune genes in the TP53 classifier in pretreatment BM
samples from TCGA-AML cases. Data were retrieved, analyzed, and visualized using cBioPortal.34 The Kaplan-Meier method was used to generate survival curves, which
were compared using a log-rank test.
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pathways related to inflammatory responses, cellular response to
cytokine stimuli, response to stress, cytokine-cytokine receptor
interactions, and interleukin-17 (IL-17)–mediated and tumor
necrosis factor–mediated signaling (Figure 3C; supplemental
Table 6).
The DE genes that we identified in primary BM samples were
further assessed in silico for potential prognostic value in TCGA-
AML cases. Data were accessed, analyzed and visualized using
the cBio cancer genomics portal.34 Abnormalities of the 18
immune genes that were overexpressed in patients with TP53-
mutated AML (by default, mRNA upregulation, amplification,
deep deletion and missense mutations) significantly correlated
with TP53 mutational status (P 5 .041; Figure 3D), higher
immune infiltration, and expression of immune checkpoints and
IFN signaling molecules (Figure 4A-B). Importantly, RFS and
OS estimates were significantly worse for TCGA-AML patients
with abnormalities in query genes (median RFS and median OS,
11.4 months) compared with patients without abnormalities in
query genes (median RFS, 24.1 months; median OS, 27.0
months; P 5 .0068 and P 5 .0009, respectively; Figure 4C). By
contrast, the 16 immune genes that were downregulated in
patients with TP53-mutated AML (supplemental Table 5) carried
no prognostic significance (supplemental Figure 5). Taken
together, these findings suggest that the immunological TME
of TP53-mutated AML is inherently proinflammatory and IFN-g
dominant and that these molecular features are associated with
poor clinical outcomes.
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Figure 5. Integrated mRNA and protein profiling of AML cells lines with missense and truncating TP53 mutations. (A) Volcano plot (R package version 1.4.0)
showing DE mRNA species and proteins between AML cell lines with missense (Kasumi-1 cells; p.R248Q; Broad Institute Cancer Cell Line Encyclopedia) and truncating
(splice site) mutations of TP53 (KG-1 cells).30 (B) Heatmap of the top DE mRNA species and proteins between KG-1 AML and Kasumi-1 AML (unsupervised hierarchical
clustering; Euclidean distance; complete linkage). ClustVis, an online tool for clustering of multivariate data, was used for data analysis and visualization.47 (C) Heatmap of
signaling pathway scores in KG-1 and Kasumi-1 cells (unsupervised hierarchical clustering; Euclidean distance; complete linkage). Signature scores were calculated as
detailed in "Materials and methods." (D) Kaplan-Meier estimate of survival from diagnosis in TCGA-AML cases with abnormalities in DE genes between KG-1 (n 5 34) and
Kasumi-1 cells (n 5 10). KM curves (median split of signature scores) were generated using GEPIA2, an enhanced Web server for TCGA gene expression profiling and
interactive analysis (http://gepia2.cancer-pku.cn/#index). Signature scores are calculated as the mean value of log2 transcripts per million. GEPIA2 uses the log-rank (Mantel-
Cox) test to compare survival distributions.
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Truncating TP53 mutations correlate with enhanced
IFN-g and inflammatory signaling in AML cell lines
It has recently been shown that TP53 missense mutations in AML
carry a gene signature of TP53 inactivation.32 Having previously
identified IFN-g–related microenvironmental signatures that corre-
late with chemotherapy resistance in AML,15 we performed in vitro
modeling experiments with commercial AML cell lines to elucidate
the potential impact of missense TP53 mutations on IFN signaling.
DNA single-nucleotide variant amplicons, RNA and protein lysates
were prepared as detailed in Materials and Methods. The inter-assay
reproducibility of RNA and protein measurements is shown in
supplemental Figure 6A. KG-1 cells harbor a sequence change
(c.67211G.A) that affects a donor splice site in intron 6 of the TP53
gene, resulting in a loss of protein function. Kasumi-1 AML cells harbor
a known missense mutation of TP53 (R248Q). In agreement with this
knowledge, TP53 protein and RNA were not detected in KG-1 cells
(supplemental Figure 6B). The single-nucleotide variant assay
confirmed the presence of TP53 (R248Q) mutations in control HuT-
78 cells (data not shown), in accordance with available knowledge
from the COSMIC database (https://cancer.sanger.ac.uk/cosmic).
A list of DE genes between KG-1 and Kasumi-1 cells was
generated by considering false discovery rate,0.01 and$1.7-fold
change (Figure 5A). Specifically, KG-1 AML cells with a truncating,
loss-of-function TP53 mutation overexpressed genes involved in
IFN-g–mediated signaling and inflammation, including HGF, CIITA,
PIM1, OSM, STAT1, and IRF1 (Figure 5B; supplemental Table 7).
KG-1 cells also showed higher expression of PD-L1 and major
histocompatibility complex class I, which are known to be regulated
by IFN-g, at the protein level compared with Kasumi-1 cells
(supplemental Figure 6C). PI3K-Akt, NF-kB, JAK/STAT and TP53
pathway genes, as well as genes associated with T helper 17
(Th17) differentiation, were significantly enriched in KG-1 cells
(Figure 5C; supplemental Table 8). Interestingly, supplemental
Figure 6D highlights that 3 functions (pathways in cancer, PI3K-Akt
signaling, and Th17 cell differentiation) were shared between DE
genes in AML cells lines and DE genes in patients with TP53-
mutated and TP53-WT AML. To assess whether the experimentally
derived gene/protein signatures could be of potential significance
for survival prediction, we split TCGA-AML cases into 2 subgroups
with greater and lower than median gene expression. As shown in
Figure 5D, genes/proteins overexpressed in KG-1 AML (n 5 34;
supplemental Table 7) predicted for shorter OS (HR, 1.7; log-rank
P 5 .048). In contrast, genes upregulated in Kasumi-1 AML were
unable to stratify patient survival (Figure 5D).
We have recently shown that patients with IFN-g–dominant
AML are less likely to respond to induction chemotherapy.15 It
has also been reported that IFN-inducible genes mediate
resistance to genotoxic damage in solid tumor cell lines.35 To
mimic a proinflammatory TME, KG-1 and Kasumi-1 cells were
treated with 100 ng/mL IFN-g for up to 24 hours. We initially
confirmed the expression of CD119, the ligand-binding portion of
the IFN-g receptor, on AML cell lines using flow cytometry
(supplemental Figure 7A). Transcriptional changes in response to
exogenous IFN-g were prompter and more robust in Kasumi-1 cells
compared with KG-1 cells, as indicated by the higher number of DE
transcripts (supplemental Figure 7B). Both the expression of IFN-
g target genes, including STAT1, NLRC5, IRF1, and ISG15
(supplemental Figure 7C), and IFN-g–induced cytotoxicity (sup-
plemental Figure 7D) were higher in Kasumi-1 cells, suggesting
that cellular responses to IFN-g are blunted in KG-1 cells with
heightened basal IFN-g signaling. Pretreatment with Prima-1MET,
which restores the transcriptional transactivation function of mutant
TP53, was associated with induction of cell death in Kasumi-1 cells
(median 62% reduction of cell viability compared with 21% in KG-1
cells), suggesting the specificity of Prima-1MET for TP53 reactivation
(supplemental Figure 7D). The occurrence of cytotoxicity after
TP53 reactivation with Prima-1MET was antagonized by exoge-
nous IFN-g in Kasumi-1 cells, but not in KG-1 cells (supplemental
Figure 7D), indicating that Prima-1MET-treated Kasumi-1 AML
cells may receive prosurvival rather than cytotoxic signals as a result
of IFN pathway activation. Finally, Kasumi-1 cells exhibited changes
in gene expression in response to Prima-1MET, but not in response
to the MDM2 inhibitor nutlin-3, including the upregulation of
inhibitors of IFN signaling, such as SOCS1 and SOCS3, and
targets for transactivation by TP53, such as FOS and PTGS2
(supplemental Figure 7E-F; supplemental Table 8). By contrast,
transcriptomic changes were minimal in Prima-1MET–treated KG-1
AML cells (supplemental Table 9). In aggregate, in vitro experi-
ments suggest that truncating TP53 mutations may correlate with
heightened IFN signaling and with resistance to IFN-g–induced
cell cytotoxicity.
TP53-mutated patients with relapsed/refractory AML
show evidence of antileukemic activity from salvage
immunotherapy with flotetuzumab
We have previously shown that baseline IFN-g–related mRNA
profiles, including the TIS score, are associated with response to
flotetuzumab immunotherapy in patients with PIF and early-
relapse AML.15 We therefore correlated TP53mutational status
with immune landscapes and with complete responses to
flotetuzumab in a cohort of 45 patients with R/R AML, including
15 patients with TP53 mutations and/or chromosome 17p
deletions usually associated with loss of one allele of TP53 and
mutation/loss of the other (Table 2). The immune landscape of
30/45 patients in this cohort has been presented in a previous
publication.15 Baseline BM samples for immune gene expres-
sion profiling were available in 13 patients with TP53 mutations
and/or genomic loss of TP53; among these, 77% (10/13) had
Table 2. Patient characteristics (immunotherapy cohort)
All patients
(N 5 45)
Patients with TP53 mutations
and/or 17p abnormalities (n 5 15*)
Age, median (range), y 61 (27-81) 61 (27-81)
Males/females, n 24/21 8/7
AML risk stratification
(2017 ELN), n (%)
Favorable 3 (6.7) 0 (0)
Intermediate 8 (17.8) 0 (0)
Adverse 34 (75.6) 15 (100)
Secondary AML, n (%) 15 (33.3) 7 (46.7)
No. of prior lines of therapy,
median (range)
2 (1-9) 2 (1-4)
*BM samples from 13 out of 15 patients were available for immune gene expression
profiling. All 15 patients with TP53 mutations/17p abnormalities were included in clinical
analyses.
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Figure 6. Immune landscape and immunotherapy response in patients with relapsed/refractory AML with and without TP53 mutations and/or 17p
abnormalities. (A) Heat-map of immune cell type-specific scores and biological activity scores in patients with relapsed/refractory AML treated with flotetuzumab immunother-
apy. ClustVis, an online tool for clustering of multivariate data, was used for data analysis and visualization.47 (B) Waterfall plot depicting changes in BM blasts after cycle 1 of
flotetuzumab in patients with TP53 mutations and/or 17p deletion (n 5 14; a BM sample was not available in 1 patient who progressed on treatment. (C) Response to
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increased immune infiltration in the TME, and only 23% (3/13)
clustered in the immune-depleted subgroup (Figure 6A). Over-
all response rate (ORR: CR, CRi, MLFS, or partial response) in
patients with TP53 mutations and/or 17p abnormalities was
60% (9/15), with 47% (7/15) achieving complete response
(,5% BM blasts on study; Figure 6B). Individuals with TP53-
mutated AML derived benefit from flotetuzumab immunotherapy
when compared with patients with TP53-WT AML (60.0% ORR
vs 33.3% ORR, respectively; P 5 .08; Figure 6C), although this
difference failed to reach statistical significance, likely as
a result of low patient numbers. In the TP53-mutated patient
subgroup, the reduction of BM blasts relative to baseline
averaged 51.2% (Figure 6B). Time on treatment and time to
patient death and/or censoring are summarized in Figure 6D for
individuals with TP53 mutations and/or 17p deletion, including
3 patients who proceeded to receive allogeneic HSCT. In
patients harboring TP53 abnormalities who achieved a CR
(CRi), median OS was 10.3 months (range, 3.3-21.3), suggesting
that flotetuzumab immunotherapy may alleviate the negative
prognostic impact of TP53 mutations. Notably, 2 patients with
TP53 abnormalities had exceptional responses to flotetuzumab,
with a CR duration .6 months (Figure 6D).
The TIS, inflammatory chemokine, Treg, CD8, IFN-g, and PD1
gene expression scores, but not PD-L1 and markers of T-cell
exhaustion (CD244, EOMES, LAG3, and PTGER4), were
significantly higher at baseline in responders compared with
nonresponders (Figure 6E), highlighting the association be-
tween response to T-cell engagers and a T-cell–inflamed TME.
Interestingly, CD8B was the top-ranking gene associated with
response to flotetuzumab, with an area under the receiver
operating characteristic curve value of 0.879 (supplemental
Figure 8A-B). The analysis of DE genes between responders
with (n 5 8) and without (n 5 10) TP53 mutations and/or 17p
deletion identified gene sets that were specifically upregulated
(IFNG, CD8B, NKG7, and SOCS1) or downregulated (CTNNB1
and ANGPT1) in responders with TP53 abnormalities (supplemental
Figure 8C-D).
Finally, flow cytometry analyses using paired BM aspirates and
blood samples from a subgroup of patients with (n5 9) and without
TP53 abnormalities (n 5 26) showed a trend toward higher
percentages of BM CD81 T cells, but not blood CD81 T cells, in
individuals with TP53 mutations and/or 17p deletion (median
45.2% vs 28.9%; P 5 not significant; supplemental Figure 9). The
expression of activation markers CD25 and HLA-DR was lower in
BM-resident CD81 and CD41 T cells from patients with TP53
abnormalities compared with TP53-WT AML (supplemental Fig-
ure 10). Furthermore, the expression of IL-7 receptor (CD127),
a marker for long-living memory T cells, was lower in TP53-mutated
AML. In line with our findings in newly diagnosed TP53-mutated
AML, the frequency of GZMB-expressing CD81 and CD41 T cells
was higher in patients with TP53 abnormalities from the flotetuzu-
mab cohort.
Discussion
Our multicohort AML study shows that patients with mutations in
TP53, the most commonly inactivated gene in human cancer,
exhibit higher CD81 T-cell infiltration and IFN-g signaling than AML
subgroups with other risk-defining molecular lesions, including
CHIP-related mutations in ASXL1, TET2, and DNMNT3A.
Comparison of immune gene expression profiles between
primary BM samples from patients with TP53-mutated and
TP53-WT AML led to the identification of an immune gene set
that is enriched in ontologies related to IFN-g/inflammatory
responses and IL-17/tumor necrosis factor–mediated signaling
and that stratifies RFS and OS in a large cohort of TCGA-AML
cases. Similar to previous studies that computed an expression
signature of TP53-mutated breast cancer,36 our TP53-related
immune gene set showed no overlap with known TP53 pathway
genes, probably owing to variations in the type of mutants
analyzed. IL-17 can exert protumoral roles early in inflamma-
tion and cancer initiation.37 IL-17 could contribute to multiple
myeloma pathobiology by promoting tumor cell growth and
colony formation, as well as increased myeloma growth in murine
xenograft models.38 The correlation between TP53 deregulation
and IL-17 overexpression remains to be confirmed in larger AML
series.
In vitro modeling experiments using commercial AML cell lines
with known mutations of TP53 allowed us to identify a set of DE
RNAs/proteins between KG-1 and Kasumi-1 cells and suggest
that TP53 inactivation, which is frequent among TP53 missense
mutants,32,39 is associated with the upregulation of IFN-g
pathway molecules, Th17 genes, and intermediates involved in
JAK/STAT and PI3K-Akt signaling and the proinflammatory NF-
kB pathway. Abnormalities of the DE RNAs/proteins in the KG-1
AML signature correlated with higher BM immune infiltration and
TP53 mutations in TCGA cases and were prognostic, as
suggested by the significant separation of the survival curves.
In sharp contrast, genes/proteins overexpressed in Kasumi-1
cells harboring a missense mutation of TP53 were unable to
stratify survival in TCGA cases. Furthermore, IFN-g induced
more rapid and robust transcriptional changes in Kasumi-1 cells
compared with KG-1 cells, with the latter also being less sensitive to
IFN-g–induced cytotoxicity. These mechanistic findings are in line
with previous reports that correlate an increased expression of
IFN-g–related mRNA signature scores with poorer OS esti-
mates in patients with AML treated with curative intent on a “7
1 3” chemotherapy backbone.15 Prolonged IFN-g signaling
can also activate a multigenic program conferring resistance to
DNA damaging agents, including radiotherapy and chemother-
apy, in preclinical models of solid tumors.40 Intriguingly, loss-
of-function mutations of BRCA1, a tumor suppressor gene
Figure 6. (continued) flotetuzumab in relation to TP53 abnormalities (x2 test). (D) Swimmer plot showing time on treatment and time to death and/or censoring in relation
to clinical response in the 15 patients with TP53 mutations and/or 17p deletion with genomic loss of TP53. Response criteria are described in "Materials and methods."
(E) TIS, inflammatory chemokine, Treg cell, CD8, IFN-g, PD1, PD-L1, and exhaustion mRNA scores in baseline BM samples from patients with TP53 mutations and/or 17p
deletion. Complete responses were defined as either CR, CR with partial hematological recovery, CRi, or MLFS. Data were compared using the Mann-Whitney U test for
unpaired determinations. CR, complete remission; CRh, complete remission with partial hematopoietic recovery; FU, follow-up; OB, other benefit (.30% decrease of BM
blasts relative to baseline); NR, no response; PD, progressive disease; SD, stable disease.
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involved in DNA repair and maintenance of genome integrity,
have also been shown to correlate with hyperactive IFN-g
signaling at baseline and with altered cellular responses of
breast and ovarian cancer cells to IFN-g, including partial
resistance to cytotoxicity.41
Treatment of Kasumi-1 AML cells with Prima-1MET was associated
with the upregulation of inhibitors of IFN signaling, including
SOCS1 and SOCS3, suggesting that TP53 missense mutations,
which carry a gene signature of TP53 inactivation,32 may lead to
enhanced IFN signaling. Pharmacological TP53 reactivation is
actively being pursued in patients with AML. MDM2 is an E3
ubiquitin ligase that binds to TP53 and induces its proteasomal
degradation. Treatment with DS-5272, an inhibitor of the TP53-
MDM2 interaction, in mouse models of AML was associated with
the upregulation of inflammatory and IFN-associated genes, including
PD-L1, and translated into enhanced antileukemia control.42
Whether TP53 reactivation in patients with cancer is associated
with immune-mediated therapeutic effects remains to be established
in future clinical trials.
Post-hoc analyses of our cohort of patients with R/R AML treated
with flotetuzumab suggest that immunotherapy may be efficacious
in the salvage setting in individuals with altered TP53 status, who
had a mean 51.2% reduction of BM blasts and showed complete
responses in 47% of cases.
Responders showed intermediate-to-high immune infiltration at
baseline and higher TIS, inflammatory chemokine, Treg, IFN-g, and
CD8 T-cell scores, but not PD-L1 and markers of T-cell exhaustion,
compared with nonresponders, suggesting that the presence
of TP53 abnormalities does not hamper the response to T-cell
engagers providing an inflammatory TME is present. Further-
more, both CD8B and IFNG were higher at baseline in responders
with TP53 abnormalities compared with responders having
TP53-WT AML. Genes previously implicated in T-cell exclusion
from melanoma lesions, such as CTNNB1,43 and angiogenesis-
mediated suppression of cell cytotoxicity (ANGPT1) were
preferentially expressed in TP53-WT AML, potentially account-
ing for the observed differences in immune infiltration.
R/R patients with TP53 abnormalities that responded to flotetuzu-
mab experienced a median OS of 10.3 months. Interestingly, 2
patients in the TP53-mutated cohort had exceptional responses to
flotetuzumab, with a CR duration .6 months. The molecular and
clinical determinants of extraordinary responses in patients with
cancer are actively being investigated.44,45 Broader cohorts of
TP53-mutated AML will be needed to identify immune correlates of
unusual outcome in response to flotetuzumab and other investiga-
tional immunotherapies.
Our results also point to the establishment of an inherently
immunosuppressive and IFN-g–driven TME in patients with TP53-
mutated AML. Previously described gene expression–based pre-
dictors of response to immune checkpoint blockade in solid tumors,
such as the TIS score,20,21 as well as immune checkpoints PD-L1,
TIGIT, and LAG3 and markers of immune senescence, were
overexpressed in AML with TP53 mutations relative to other
molecular subtypes. Some of the characterized genes may
therefore contribute mechanistically to the poor prognosis associ-
ated with TP53-mutated AML through the induction of immune
escape.46 Hence, patients with TP53 mutations might require
combinatorial immunotherapy approaches that also target Treg
cells and immune checkpoints, either concomitantly or sequentially.
In conclusion, our study shows that TP53 mutations in AML are
associated with higher T-cell infiltration, expression of immune
checkpoints, and IFN-g–driven transcriptional programs. These
gene expression profiles that have previously been shown to enrich
in patients with chemotherapy resistance correlate with disease
control in response to flotetuzumab immunotherapy.15 Our findings
therefore encourage further studies of T-cell–targeting immuno-
therapeutic approaches in larger series of patients with AML who
harbor this molecular lesion.
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